These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18804288)

  • 1. Identification and development of new therapeutics for multiple sclerosis.
    Linker RA; Kieseier BC; Gold R
    Trends Pharmacol Sci; 2008 Nov; 29(11):558-65. PubMed ID: 18804288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune mechanisms of new therapeutic strategies in MS: teriflunomide.
    Claussen MC; Korn T
    Clin Immunol; 2012 Jan; 142(1):49-56. PubMed ID: 21367665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
    Linker RA; Lee DH; Stangel M; Gold R
    Expert Rev Neurother; 2008 Nov; 8(11):1683-90. PubMed ID: 18986239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.
    Coisne C; Mao W; Engelhardt B
    J Immunol; 2009 May; 182(10):5909-13. PubMed ID: 19414741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in MS: mechanisms of action.
    Bielekova B; Becker BL
    Neurology; 2010 Jan; 74 Suppl 1(Suppl 1):S31-40. PubMed ID: 20038761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New immunosuppressants with potential implication in multiple sclerosis.
    Gonsette RE
    J Neurol Sci; 2004 Aug; 223(1):87-93. PubMed ID: 15261567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis therapeutic pipeline: opportunities and challenges.
    Krieger S
    Mt Sinai J Med; 2011; 78(2):192-206. PubMed ID: 21425264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotoxicity profile of natalizumab.
    Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
    J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
    Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
    Stüve O
    J Neurol Sci; 2008 Nov; 274(1-2):39-41. PubMed ID: 18474372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating multiple sclerosis with monoclonal antibodies.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2008 Mar; 8(3):433-55. PubMed ID: 18345973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
    Trebst C; Voss E; Skripuletz T; Stangel M
    Curr Med Chem; 2010; 17(7):640-50. PubMed ID: 20088763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA; Roberts RJ; Schlein AL
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of chemokine signaling in Multiple Sclerosis.
    Hamann I; Zipp F; Infante-Duarte C
    J Neurol Sci; 2008 Nov; 274(1-2):31-8. PubMed ID: 18706659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.
    Krumbholz M; Meinl I; Kümpfel T; Hohlfeld R; Meinl E
    Neurology; 2008 Oct; 71(17):1350-4. PubMed ID: 18936427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis.
    Toubi E; Nussbaum S; Staun-Ram E; Snir A; Melamed D; Hayardeny L; Miller A
    J Neuroimmunol; 2012 Oct; 251(1-2):45-54. PubMed ID: 22846497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.